Clinical Trials Logo

Resectable Esophageal Cancer clinical trials

View clinical trials related to Resectable Esophageal Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05307835 Recruiting - Clinical trials for Resectable Esophageal Cancer

Neoantigen Vaccine in Esophagus Cancer Patients Following Neoadjuvant Therapy and Surgical Resection

Start date: December 2, 2021
Phase: Phase 1
Study type: Interventional

This research study is evaluating a new type of esophagus cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for esophagus cancer patients who have completed adjuvant therapy following neoadjuvant therapy and surgical resection. The purpose of the clinical study is evaluating the safety, tolerability and partial efficacy of the personalized neoantigen cancer vaccine in the treatment of resectable esophagus cancer, so as to provide a new personalized therapeutic strategy.

NCT ID: NCT04006041 Recruiting - Clinical trials for Resectable Esophageal Cancer

Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer

Start date: June 25, 2019
Phase: Phase 2
Study type: Interventional

Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal cancer (EC). However, only 20% to 40% of EC patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with favorable prognosis. Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in advanced EC. The aim of this study was to evaluate the efficacy and safety of the combination of toripalimab (an anti-PD-1 antibody) combined with neoadjuvant CRT in locally advanced esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT03490292 Active, not recruiting - Clinical trials for GastroEsophageal Cancer

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Start date: May 29, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a 2 part Phase I/II clinical trial evaluating the safety, tolerability and efficacy of avelumab in combination with chemoradiation in patients with resectable esophageal and gastroesophageal cancer. Part 1: This is the run-in phase of the trial. This portion will determine the safety and tolerability of avelumab in combination with chemoradiotherapy in 6 patients. The proposed combination will be considered as safe if dose limiting toxicities are observed in at most 1 patient. Part 2: This is a Phase 2 portion of the trial, which will evaluate the efficacy of the proposed treatment regimen in patients with stage II/III resectable esophageal and gastroesophageal cancer

NCT ID: NCT01858805 Completed - Clinical trials for Resectable Esophageal Cancer

Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer

Start date: April 2010
Phase: N/A
Study type: Observational

Despite the availability of several preoperative diagnostic techniques, accurate pretreatment staging of esophageal cancer (EC) remains challenging. Therefore, The investigators evaluated the prognostic significance of circulating tumor cells (CTCs) in patients with EC.

NCT ID: NCT00827671 Terminated - Clinical trials for Resectable Esophageal Cancer

Study of Combination of Cetuximab and Radiotherapy Added to the Standard Treatment for Oesophageal Adenocarcinoma

TRACC
Start date: March 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the addition of the combination between cetuximab and radiotherapy to the standard chemotherapy for resectable oesophageal cancer is safe and adds efficacy.